{
    "clinical_study": {
        "@rank": "124649", 
        "brief_summary": {
            "textblock": "This study is designed to test the hypothesis that African-Americans respond less well to\n      combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have\n      chronic hepatitis C genotype 1 and who were not previously treated with either interferon or\n      ribavirin.  Reasons for differences in response, regardless of race, will be studied."
        }, 
        "brief_title": "Hepatitis C Antiviral Resistance in African-Americans", 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion:\n\n          -  Age between 18 and 70 years at screening\n\n          -  Black/African American or White/Caucasian\n\n          -  Born in the United States\n\n          -  Quantifiable Serum HCV RNA\n\n          -  Hepatitis C genotype 1\n\n          -  Liver biopsy consistent with chronic hepatitis C\n\n          -  Negative urine pregnancy test\n\n          -  Males and Females must be using two reliable forms of effective contraception while\n             on drug and during follow-up.\n\n        Exclusion:\n\n          -  Previous treatment with interferon or ribavirin\n\n          -  Positive test at screening for anti-HIV\n\n          -  Positive test for HBsAg\n\n          -  Alcohol consumption of more than two drinks/day\n\n          -  History of other chronic liver disease\n\n          -  Pregnant or breast-feeding women\n\n          -  Male partners of women who are pregnant or    contemplating pregnancy\n\n          -  Neutrophil count <1000 cells/mm3\n\n          -  Hgb <11 g/dl in women or 12 g/dl in men\n\n          -  Platelet count <75,000 cells/mm3.\n\n          -  Thalassemia, spherocytosis, history of GI    bleeding or those at increased risk of\n             anemia\n\n          -  Serum creatinine level >1.5 times the upper limit of normal at screening or CrCl <\n             75cc/min\n\n          -  Current dialysis\n\n          -  Alcohol or drug abuse within 6 months\n\n          -  Current (<6 months)severe psychiatric disorder\n\n          -  History of immunologically mediated disease\n\n          -  Decompensated liver disease\n\n          -  High risk cardiovascular/coronary artery disease\n\n          -  Severe seizure disorder or anticonvulsant use\n\n          -  Solid organ or bone marrow transplantation\n\n          -  Thyroid disease poorly controlled on  prescribed medications\n\n          -  History or other evidence of retinopathy\n\n          -  Chronic use of oral steroids\n\n          -  Inability or unwillingness to provide informed consent or abide by the study protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "400", 
        "firstreceived_date": "June 5, 2002", 
        "id_info": {
            "nct_id": "NCT00038974", 
            "org_study_id": "Virahep-C  (completed)", 
            "secondary_id": "U01 DK60329"
        }, 
        "intervention": [
            {
                "intervention_name": "Pegylated interferon", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Interferons", 
                "Ribavirin"
            ]
        }, 
        "keyword": [
            "Hepatitis C", 
            "Interferon", 
            "Ribavirin", 
            "Efficacy", 
            "Viral load", 
            "Genetics", 
            "Cytokines", 
            "Immunology"
        ], 
        "lastchanged_date": "March 15, 2011", 
        "link": {
            "description": "Virahep-C study web site", 
            "url": "http://www.virahepc.org"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "University of California, San Francisco"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "University of Maryland School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University of Michigan Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "New York-Presbyterian Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "University of North Carolina"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038974"
        }, 
        "source": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2011"
    }, 
    "geocoordinates": {
        "Beth Israel Deaconess Medical Center": "42.358 -71.06", 
        "New York-Presbyterian Medical Center": "40.714 -74.006", 
        "Rush University": "41.878 -87.63", 
        "University of California, San Francisco": "37.775 -122.419", 
        "University of Maryland School of Medicine": "39.29 -76.612", 
        "University of Miami School of Medicine": "25.789 -80.226", 
        "University of Michigan Medical Center": "42.281 -83.743", 
        "University of North Carolina": "35.913 -79.056"
    }
}